Taflotan (tafluprost; Santen Oy), a benzalkonium chloride (BAK)-free prostaglandin analogue for the treatment of glaucoma, has received marketing authorization in Denmark and Germany, making it the first preservative-free prostaglandin eye drop to be approved.
OTEurope Readership Survey
Moria's new microkeratome, One Use-Plus SBK, outperforms Femto-LASIK, it was announced at this year's meeting of the American Society of Cataract and Refractive Surgery (ASCRS).
Methods of attempting to prevent postoperative endophthalmitis vary widely across the United Kingdom, according to a study published in the May 2008 issue of Eye.
Study of the use of collagen crosslinking with riboflavin has been limited. Early experience with this technique, however, suggests it safely increases corneal rigidity and limits ectasia progression.
Phakic intraocular lenses (IOLs) have failed to live up to their promise, according to an opinion expressed at this year's meeting of the French Society of Ophthalmology (SFO).
Poor health literacy is contributing to disease progression among glaucoma patients, according to a study published in the May 2008 issue of the Archives of Ophthalmology.
Using a microcatheter to perform 360° trabeculectomy is a safer and more consistent way to treat congenital glaucoma than traditional trabeculectomy, according to information presented at this year's meeting of the American Glaucoma Society (AGS).
Extraction of cataracts lowers intraocular pressure (IOP) to normal levels in glaucoma patients, and may in fact be a better treatment option than combined surgery, according to a study presented at this year's meeting of the Italian Society of Ophthalmology.
V2 Vantage DX, a new generation of retinal imaging software, has been released by Optos plc, UK.
The use of green gold nanoparticles may have a place in the therapy of cancer and ophthalmic diseases, according to a study presented at this year's meeting of the Association for Research in Vision & Ophthalmology (ARVO).
Attend the Heidelberg symposium, Next Generation Retinal Imaging: Multi-Modality Tracking Laser Tomography, at the 8th Euretina meeting in Vienna
The incidence of suspected endophthalmitis in patients who have received intravitreal anti-vascular endothelial growth factor (VEGF) treatments in a community setting is very low, according to a study published in the May 2008 issue of the American Journal of Ophthalmology.
Diabetes-induced changes to 37 separate proteins of the vitreous may be the key to understanding the mechanisms of diabetic retinopathy (DR), according to a study to be published in the June issue of the Journal of Proteome Research.
Clinical doses of Avastin (bevacizumab; Genentech) and Lucentis (ranibizumab; Novartis) are equally effective in neutralizing vascular endothelial growth factor (VEGF), while Macugen (pegaptanib; Pfizer) has no effect, according to a study published online ahead of print by the Journal of Investigative Ophthalmology.
Wavefront-guided LASIK is safe and effective in correcting residual refractive error after diffractive multifocal IOL implantation, according to a study published in the March 2008 issue of the Journal of Refractive Surgery.
Diagnoses using digital slit-lamp images are comparable to diagnoses using 35 mm photographic slides for some anterior segment abnormalities, according to a study published online ahead of print in Eye.
The incidence of capsular block syndrome (CBS), although rare, can be increased by design features of lenses implanted during cataract surgery, according to a study published in the March 2008 issue of the Journal of Cataract & Refractive Surgery.
Refractive surgery in children with severe anisometropia or ametropia produces relatively stable results, according to a study published in the American Orthoptic Journal.
The FDA has cleared the iFS Advanced Femtosecond Laser (AMO), which is now available for order.
Patients with a positive family history of glaucoma are 10 times as likely to have visual field (VF) defects at the time of their diagnosis, according to a study published in the April issue of Clinical & Experimental Ophthalmology, the official Journal of the Royal Australian and New Zealand College of Ophthalmologists.
Taflotan (tafluprost; Santen Oy), a benzalkonium chloride (BAK)-free prostaglandin analogue for the treatment of glaucoma, has received marketing authorization in Denmark and Germany, making it the first preservative-free prostaglandin eye drop to be approved.
The World Glaucoma Day inspired glaucoma specialists around the world to rally local support in order to undertake an enormous task: to reduce the number of people who are unnecessarily going blind from a treatable condition.
QLT Plug Delivery, Inc. has demonstrated proof of concept of its punctal plug drug delivery technology, showing that it is both well tolerated and effective at lowering intraocular pressure (IOP).
Vidus Ocular, Inc, the developer of the Aquashunt device for glaucoma, has been acquired by OPKO Health, Inc.
The European Commission and the European Patent Office (EPO) have named Optos plc as European Inventor of the Year in the SME and Research category.
VIEW 2, a Phase III trial evaluating the efficacy and safety of VEGF Trap (afilbercept; Regeneron) versus Lucentis (ranibizumab; Novartis) administered by intravitreal injection for the treatment of neovascular age-related macular degeneration (wet AMD), has dosed its first patient.
A pilot study evaluating the safety and efficacy of Medidur FA (fluocinolone acetonide; Alimera) with Lucentis (ranibizumab; Novartis) against exudative age-related macular degeneration (wet AMD) has begun patient enrolment.
Vitamin E supplements do not help to prevent cataract, according to a study published in the May 2008 issue of Ophthalmology.
A hybrid contact lens designed for eyes that have suffered corneal trauma or undergone either refractive surgery or penetrating keratoplasty has been launched by SynergEyes Inc, US. The SynergEyes PS lens can also be used in eyes with degenerative corneal conditions.
